NDC product
Rolvedon
NDC 76961-101 · Spectrum Pharmaceuticals, Inc.
Key facts
| Product NDC | 76961-101 |
|---|---|
| Proprietary name | Rolvedon |
| Nonproprietary name | eflapegrastim-xnst |
| Substances | EFLAPEGRASTIM |
| Dosage form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | Spectrum Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761148 |
| Pharmacologic classes | Granulocyte Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC] |
| Marketing start | Oct 18, 2022 |
| Marketing end | Aug 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory